RecruitingNot Applicable

Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery

China204 participantsStarted 2026-04-07

Plain-language summary

This prospective, randomized controlled study aims to evaluate the efficacy and safety of electroacupuncture combined with 5-HT3 receptor inhibitor for preventing postoperative nausea and vomiting (PONV) in high-risk patients undergoing thoracoscopic lung cancer surgery. The primary outcome is the incidence of PONV within 24 hours after surgery.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years; * American Society of Anesthesiologists (ASA) physical status I-III; * Body mass index (BMI) 18-30 kg/m²; * Scheduled for elective video-assisted thoracoscopic surgery (VATS) lobectomy, segmentectomy, or wedge resection; * Expected to receive postoperative opioid analgesia, with an Apfel risk score ≥ 3; * Normal pulmonary function, without severe cardiovascular, hepatic, or renal abnormalities; * No infection around the acupuncture sites; * Voluntary written informed consent provided by the subject. Exclusion Criteria: * Severe systemic diseases, such as cardiovascular, hepatic, or renal abnormalities, or poor pulmonary function; * Subjects with cognitive dysfunction or psychological disorders; * History of previous esophageal or gastric surgery; * Hypersensitivity to acupuncture or any study medications; * Severe infection or history of surgery around the acupuncture sites; * Pregnant or lactating women; * Long-term opioid use; * Conversion to open surgery; * Acupuncture treatment received within 1 month prior to enrollment.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Incidence of postoperative nausea and vomiting (PONV) within 24 hours after surgery

Timeframe: within 24 hours postoperatively

Trial details

NCT IDNCT07515027

SponsorShanghai Chest Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-11-01

Contact for this trial

Deputy Chief Physician

+86 18017321631 caixiaoyue2007@163.com

View on ClinicalTrials.gov More PONV trials